Using pegvisomant to treat children with excess growth hormone

An Open-Label Phase 3 Study of the Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess

This study is testing whether pegvisomant can safely help children and teens with excess growth hormone, especially those with gigantism, feel better when other treatments haven't worked.

Quick facts

• Phase: PHASE3
• Study type: Interventional
• Enrollment: 120 (estimated)
• Ages: 2 Years to 18 Years
• Sex: All
• Sponsor: National Institutes of Health Clinical Center (CC) (nih)
• Drugs / interventions: radiation
• Locations: 1 site (Bethesda, Maryland)
• Trial ID: NCT03882034 on ClinicalTrials.gov

What this trial studies

This clinical trial aims to evaluate the safety and efficacy of pegvisomant in children and adolescents aged 2 to 18 who have growth hormone excess, specifically those with gigantism. The study will last for 60 weeks and will include multiple visits for medical history assessments, physical exams, and various tests including blood tests and heart and liver evaluations. Participants will be monitored for changes in insulin-like growth factor type 1 (IGF-1) levels and overall clinical improvement, particularly in those who have not responded to existing treatments like surgery or radiation therapy.

Who should consider this trial

Good fit: Ideal candidates are children and adolescents aged 2-18 with confirmed growth hormone excess who have not responded to or are ineligible for standard treatments.

Not a fit: Patients who do not have growth hormone excess or those who have not exhausted other treatment options may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new effective option for managing growth hormone excess in children, potentially improving their health outcomes and quality of life.

How similar studies have performed: While pegvisomant has shown effectiveness in adults with acromegaly, its use in children is less established, making this approach relatively novel.

Eligibility criteria

* INCLUSION CRITERIA:
* Subjects who are eligible for enrollment must meet the following eligibility criteria:

Cohort 1: Patients with GH excess

* Males and females 24 months to \<18 years at enrollment
* Active GH excess as demonstrated by the following:

  * IGF-1 greater than the upper limit of normal for age and sex during screening (\>+2 SD) and
  * Abnormal GH levels as demonstrated by inability to suppress to \<1 ng/mLwith older radioimmunoassays or \<0.4ng/ml with sensitive immunoradiometric or immunochemiluminescent assays within 2 hours during Oral Glucose Tolerance Test (OGTT) after the administration of 1.75gr/kg (max 75gr) of glucose or elevated GH secretion profile during overnight sampling.
* History of inadequate response to trans-sphenoidal surgery or radiation therapy for GH secreting pituitary tumor, or inability to tolerate surgery or radiation therapies or patient deemed inappropriate candidate for surgery and/or pituitary radiation therapy, as determined by review of the medical records by the Principal Investigator. The evaluation of the patient should be performed at 3 months after the surgery date in order to ensure that there is persistent GH excess after the transsphenoidal resection of the tumor unless there are clear evidence of persistent disease, e.g. residual tumor, based on the PI s assessment. If the patient has received irradiation, there is no minimum time to be considered before enrolling in the study. The effects of radiation therapy take place over many years after receiving it (mean time to remission for stereotactic radiation therapy of 12-60 months), and, thus, a medical therapy is required during that period.
* Patient is either not receiving any other medication for GH excess or is receiving stable dose/frequency of other medications for the treatment of GH excess prior to initiation of pegvisomant and no further adjustment or addition of new medication is made for the duration of the study.

  * Medications that may be co-administered for GH excess include but are not limited to: IM/SC/oral first- or second-generation somatostatin analogues (octreotide, lanreotide, pasireotide), oral dopamine agonist (cabergoline) and any other medication/formulation that may become available during this study. For each medication, its specific formulation and route of administration, patient will need to be on stable dose/frequency for a duration that is at least the minimum time recommended for adjusting the dose by the manufacturer which usually incorporates the time needed to reach plasma steady-state levels and a new plateau on the effect of the medication on IGF-1 (cabergoline: 4 weeks; SC octreotide/pasireotide administered twice or three times daily: 2 weeks; oral octreotide: 2 weeks; depot IM octreotide/SC lanreotide/IM pasireotide administered Q4 weeks: 3 months). The duration needed for the stable dose for patients on alternative schedules of administration of the above or other medications will be assessed based on available information and the longest estimated interval to achieve the full effect.
  * If a patient has been receiving a medication for GH excess but is not interested to continue that medication a minimum period of 6-weeks of discontinuation of the medication will be required for washout. This period was defined in the prior version of the protocol and is designed to minimize the time the patient may not be receiving any treatment for GH excess.
* Able to provide consent/assent if developmentally appropriate
* Willing to use non-hormonal method of contraception in patients of reproductive potential from the start of the study until at least 28 days after they stop the medication. Females of reproductive age (Tanner 3 or more, and/or having menstrual cycle) will be educated on the risks of unknown potential fetal harm while using the investigational medication, and they will be educated on the alternative preventative methods for contraception (condoms). Females already receiving oral contraceptive pills (OCPs) will be evaluated by gynecology consult service to discuss effective non-hormonal contraception. Sexually active female subjects must agree to use an effective non-hormonal contraception for the duration of the study.
* Have a primary health care provider in home location who will perform regular height and weight measurements, vital signs, and safety labs.

Height and weight will be requested to be performed according to the published methods included in the CDC-NHANES manual on anthropometry procedures manual (Supplementary Material). They will be plotted on the respective growth charts produced by the CDC for the US population (Supplementary Material).

Cohort 2: Parents

-Biological parents of a participant enrolled in the study enrolled for anthropometric measurements only.

EXCLUSION CRITERIA:

Cohort 1: Patients

An individual who meets any of the following criteria will be excluded from participation in this study:

* Liver function abnormalities (ALT, AST) greater than or equal to 3 x ULN
* Positive pregnancy test in females, current pregnancy and/or female patients who are breastfeeding.
* Patients currently using opioids. Opioids induce altered metabolism of pegvisomant. Since this is a phase 3 study, opioids may affect the PK studies to be performed and, thus, chronic use of opioids (\>2 weeks) will be an exclusion criterion.
* Patients with any medical, physical, psychiatric, or social condition, which, in the opinion of the investigators, would make participation in this protocol not in their best interest, will be excluded from the study. Patients who are critically ill, unstable, or with severe organ failure that may affect/limit the endocrine evaluation and place unsustainable demands on CC or NICHD resources will be excluded.

Cohort 2: Patients Parents:

Subjects enrolled as parents of patients do not have to be tested for the above exclusion criteria as their participation is limited to anthropometric measurements (no risk).

Where this trial is running

Bethesda, Maryland

• National Institutes of Health Clinical Center — Bethesda, Maryland, United States (RECRUITING)

Study contacts

• Principal investigator: Christina Tatsi, M.D. — Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
• Study coordinator: Samah M Agabein, M.D.

Conditions: Pituitary Disease, Pediatric, Gigantism, Growth Hormone, Hormone